ClearNote Health, a company dedicated to improving cancer outcomes through early detection and aiding in the development of better drugs, has announced a collaboration with Bayer. This partnership focuses on evaluating biological mechanisms underlying patient responses and resistance to treatments for metastatic hormone-sensitive prostate cancer. The collaboration will utilize ClearNote Health’s advanced epigenomic cancer detection platform, applied to liquid biopsy samples, to monitor patient responses to prostate cancer therapies.
This initiative is aimed at providing a more in-depth understanding of the disease biology, which is crucial for advancing Bayer’s precision medicine programs specifically targeting prostate cancer. ClearNote Health’s epigenomic platform employs machine learning algorithms to identify and measure DNA-based changes in patient blood samples, which can be indicative of cancer development.
Samuel Levy, Ph.D., Chief Scientific Officer of ClearNote Health, emphasized the goal of using their platform to gain deeper insights into the disease biology of metastatic hormone-sensitive prostate cancer. He expressed enthusiasm about working with industry-leading partners to expand the platform’s applications across various cancer types, aiming to enhance precision medicine and improve patient outcomes.
ClearNote Health is a cancer detection company that focuses on identifying cancer earlier to enable better survival rates for people at risk of high-mortality cancers. The company uses standard blood draws and combines biology with artificial intelligence in its proprietary epigenomic platform to detect DNA-based changes as cancer develops. ClearNote Health has leading programs in non-invasive early detection of pancreatic and ovarian cancers in high-risk patients. The company’s first commercially available test is the Avantect™ Pancreatic Cancer Test, designed to detect pancreatic cancer signals in high-risk patients, including those recently diagnosed with Type 2 diabetes.